SCHEMBL2477634

SCHEMBL2477634

CC1CCCCN1C1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.52
EPHX1 P07099 1/20 0.47
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
PREP P48147 2/20 0.45
HRH3 Q9Y5N1 5/20 0.42
RECQL P46063 1/20 0.41
PDE4B Q07343 1/20 0.41
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
FPR2 P25090 1/20 0.40
USP30 Q70CQ3 1/20 0.39
HCAR1 Q9BXC0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477630 1.00 HPGD (0.52) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL12186260 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL223042 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL220850 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL220045 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL221146 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL222625 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL12272010 0.96 HPGD (0.50) HPGDEPHX1MEN1ALDH1A1MAPT
SCHEMBL19947116 0.92 HPGD (0.55) HPGDEPHX1MAPTPREPHRH3
SCHEMBL2479150 0.92 HPGD (0.55) HPGDEPHX1MAPTPREPHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9533995-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2017-01-03 US disclosed
EP-2569294-B1 SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-03-11 EP disclosed
US-20140315923-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-10-23 US disclosed
US-8859588-B2 Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
US-8796278-B2 Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof SANOFI (FR) 2014-08-05 US disclosed
EP-2373659-B1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-07-30 EP disclosed
EP-2569304-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-20 EP disclosed
EP-2569294-A1 SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-20 EP disclosed
EP-2569296-A1 SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-20 EP disclosed
US-20130065923-A1 SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-14 US disclosed
US-20130059874-A1 SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-07 US disclosed
US-8383814-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2013-02-26 US disclosed
US-20120238757-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-20 US disclosed
US-8217052-B2 Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof SANOFI (FR) 2012-07-10 US disclosed
WO-2011143163-A1 SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed
WO-2011143148-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed
WO-2011143162-A1 SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 WO disclosed
US-20110251225-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-10-13 US disclosed
EP-2373659-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-10-12 EP disclosed
WO-2010065798-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251225-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF HRH3, HRH4, HRH1 HPGD 469/4885EPHX1 2059/4885MEN1 2361/4885
US-20130065923-A1 SUBSTITUTED N-HETEROARYL BIPYRROLIDINE CARBOXAMIDES, PREPARATION AND THERAPEUTIC USE THEREOF HRH3, HRH4, HRH1 HPGD 1608/4885EPHX1 1635/4885MEN1 3931/4885
US-20140315923-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF CHRM2, NR3C2, NPSR1 HPGD 438/4885EPHX1 968/4885MEN1 2415/4885
US-20130059874-A1 SUBSTITUTED N-PHENYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF NR3C2, NPSR1, NPR1 HPGD 308/4885EPHX1 1331/4885MEN1 2615/4885
US-20120238757-A1 SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF HRH3, HRH4, HRH1 HPGD 469/4885EPHX1 2059/4885MEN1 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.